BioSpace News Archive

Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the second quarter ended June 30, 2023 after market close on August 10, 2023.

Roivant announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 14, 2023, to report its financial results for the quarter ended June 30, 2023, and provide a business update.

Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the second quarter of 2023.

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

ABVC BioPharma, Inc. announced that the Science Park Administration in Taiwan approved the plan for setting up a pilot Good Manufacturing Practice facility to produce Vitargus®, a groundbreaking product in retinal detachment surgery, and to pursue the process development work for manufacturing optimization.

Zynex, Inc. has the company’s Founder and CEO, Thomas Sandgaard will participate in Benzinga’s Pharma Companies vs. A Tough Macro Backdrop Free Webinar at 12:15 PM ET on August 3rd, 2023.

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the appointment of Dr. Leona Hamrick DHSc, PA-C, MSL-BC to the newly created position of Senior Director, Medical Affairs.

Quanta Dialysis Technologies® today announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication of the Quanta Dialysis System, a compact and easy-to-use hemodialysis device, for two modalities of continuous renal replacement therapy (CRRT): continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF).

CAGE Bio, Inc. (hereinafter “CAGE Bio”) a biotechnology company focused on developing innovative drug therapies for localized treatment of immuno-dermatological disorders, today announced positive results from its randomized, vehicle controlled, phase 2 study evaluating the safety and efficacy of CGB-500, an ionic liquid formulation of 1% Tofacitinib, in patients with Atopic Dermatitis (AD).

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients with high unmet needs, and the Choroideremia Research Foundation (CRF), the largest organization in the world focused on the search for a cure for choroideremia (CHM), have partnered to advance a potential new treatment for patients with CHM.